Search Within

Andrew D Zelenetz

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Meeting Abstract (57)
  2. Journal Article (30)
  3. Research Letter (3)
  4. Editorial (1)
Groups
  1. Center for Hematologic Malignancies (91)
  2. Department of Medicine (91)
  3. Hematologic Malignancies, Division of (91)
  4. Lymphoma (91)
  5. Sloan Kettering Institute Postdocs (91)
  6. Survivorship Research (60)

More Groups

People
  1. Maria Palomba (65)
  2. Anita Kumar (63)
  3. Paul Hamlin (63)
  4. Ariela Noy (62)
  5. Alison Moskowitz (58)
  6. Steven Horwitz (57)

More People

Years
  1. 2025 (2)
  2. 2024 (5)
  3. 2023 (17)
  4. 2022 (10)
  5. 2021 (13)
  6. 2020 (16)

More Years

Publications
  1. Blood (46)
  2. Hematological Oncology (9)
  3. Journal of Clinical Oncology (6)
  4. Blood Cancer Journal (5)
  5. Blood Advances (4)
  6. Haematologica (4)

More Publications

Publishers
  1. American Society of Hematology (50)
  2. Wiley Blackwell (9)
  3. American Society of Clinical Oncology (6)
  4. Nature Publishing Group (5)
  5. Ferrata Storti Foundation (4)
  6. Taylor & Francis Group (3)

More Publishers

Results (91)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of nivolumab plus doxorubicin, vinblastine, dacarbazine as frontline therapy in older adults with Hodgkin lymphoma
    Journal Article

    Torka, P.; Feldman, T.; Savage, K. J.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Capadona, C.; Subzwari, S.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: Real-life experience
    Journal Article

    Cassanello, G.; Drill, E.; Rivas-Delgado, A.; Okwali, M.; Isgor, I.; Caron, P. C.; Epstein-Peterson, Z.; Ghione, P.; Hamlin, P. A.; Lue, J. K.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
    Research Letter

    Lue, J. K.; Luttwak, E.; Rivas-Delgado, A.; Irawan, H.; Boardman, A.; Caron, P. C.; David, K.; Epstein-Peterson, Z.; Falchi, L.; Ghione, P.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Validation of LymphGen classification on a 400-gene clinical next-generation sequencing panel in diffuse large B-cell lymphoma: Real-world experience from a cancer center
    Research Letter

    Zhu, M. L.; Drill, E.; Joffe, E.; Salles, G.; Rivas Delgado, A.; Zelenetz, A.; Palomba, M. L.; Arcila, M.; Dogan, A.
    Haematologica (2024)

    Fulltext@MSK | Save
  • Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
    Journal Article

    Montoya, S.; Bourcier, J.; Noviski, M.; Lu, H.; Thompson, M. C.; Chirino, A.; Jahn, J.; Sondhi, A. K.; Gajewski, S.; Tan, Y. S.; more...
    Science (2024)

    Fulltext@MSK | Save
  • Diffuse large B-cell lymphoma involving osseous sites: Utility of response assessment by PET/CT and good long-term outcomes
    Journal Article

    Ghione, P.; Ahsanuddin, S.; Luttwak, E.; Varela, S. B.; Nakajima, R.; Michaud, L.; Gupta, K.; Navitski, A.; Straus, D.; Palomba, M. L.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Genetic alterations of follicular lymphoma can predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Fregonese, B.; Seshan, V.; Hajj, C.; Cederquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of early histological transformation on survival in patients with follicular lymphoma
    Meeting Abstract

    Luttwak, E.; Qiu, A.; Okwali, M.; Rivas-Delgado, A.; Isgor, I.; Boardman, A. P.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; more...
    Blood (2023)

    Fulltext@MSK | Save